(Q34407909)

2 August 2017

Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea (English)

1 reference

2 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Akira Kubota

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Akira Kanamori

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Akira Kuroe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Nobuo Takahashi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Tatsuhiko Saito

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Ikuro Matsuba

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Koichiro Nabe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Takeshi Kurose

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Yutaka Seino

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

11 February 2014

1 reference

Journal of Diabetes Investigation

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

445-448

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

9 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

GIP and GLP-1, the two incretin hormones: Similarities and differences

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Treating diabetes today: a matter of selectivity of sulphonylureas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Diabetes mellitus, fasting glucose, and risk of cause-specific death

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

10-year follow-up of intensive glucose control in type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR) and cDNA

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4210074

Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance

6 July 2018

1 reference

Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes

21 January 2018

1 reference

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

Secondary sulfonylurea failure: comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide

21 January 2018

1 reference

Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25411605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25411605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25411605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/JDI.12182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25411605%20AND%20SRC:MED&resulttype=core&format=json